LEXINGTON, Mass., July 17, 2018 -- Pulmatrix, Inc. (PULM) announced today that all dosing and follow up visits have been completed for Part 3 of the ongoing first-in-human study of Pulmazole (PUR1900) - an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for ...